TuHURA Biosciences (HURA) Stock Price, News & Analysis

Company Overview

TuHURA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is aimed at addressing primary and acquired resistance to existing cancer immunotherapies, including immune checkpoint inhibitors.

TuHURA’s lead investigational product, IFx-2.0, is an intratumoral cancer immunotherapy designed to stimulate a patient’s immune system to recognize and attack tumor cells. The company is evaluating the candidate in clinical studies involving advanced solid tumors, including melanoma, with the goal of improving responses in patients whose cancers have not responded adequately to available treatments.

TuHURA is headquartered in Tampa, Florida, and conducts its drug-development activities through clinical research and collaborations primarily in the United States. The company became publicly traded on Nasdaq under the symbol HURA following a business combination with Kintara Therapeutics. James Bianco, M.D., serves as president and chief executive officer.

Key Stats

• Today's Range: $2.05 to $2.15
• 50-Day Range: $2.00 to $2.47
• 52-Week Range: $0.41 to $3.43
• Volume: 149,262 shs
• Average Volume: 183,408 shs
• Market Capitalization: $133.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

TuHURA Biosciences Stock Analysis - MarketRank™

TuHURA Biosciences scored higher than 35% of companies evaluated by MarketBeat, and ranked 729th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TuHURA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

TuHURA Biosciences has a consensus price target of $9.00, representing about 328.6% upside from its current price of $2.10.

Amount of Analyst Coverage

TuHURA Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for TuHURA Biosciences are expected to decrease in the coming year, from ($0.55) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TuHURA Biosciences is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TuHURA Biosciences is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TuHURA Biosciences has a P/B Ratio of 6.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.49% of the float of TuHURA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

TuHURA Biosciences has a short interest ratio ("days to cover") of 32.58, which indicates bearish sentiment.

Change versus previous month

Short interest in TuHURA Biosciences has recently increased by 0.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TuHURA Biosciences does not currently pay a dividend.

Dividend Growth

TuHURA Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.71

News Sentiment

TuHURA Biosciences has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for TuHURA Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for HURA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

3 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.06% of the stock of TuHURA Biosciences is held by insiders.

Percentage Held by Institutions

0.62% of the stock of TuHURA Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HURA
• Previous Symbol: NASDAQ:HURA
• CIK: 1498382
• Web: tuhurabio.com
• Phone: (813) 875-6600
• Fax: 604-608-5685
• Employees: 22
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TuHURA Biosciences: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +328.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -156.47%
• Return on Assets: -106.98%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 0.18
• Quick Ratio: 0.18

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 6.18

Miscellaneous

• Outstanding Shares: 63,730,000
• Free Float: 59,865,000
• Market Cap: $133.83 million
• Optionable: N/A
• Beta: -0.02